TOIIW — The Oncology Institute, Inc.

Summary of The Oncology Institute (TOIIW) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue Growth: Q4 2025 revenue reached $142 million, a 41.6% increase year-over-year, with full-year revenue surpassing $500 million for the first time, up approximately 28% from $393.4 million in 2024.
• Adjusted EBITDA: Achieved positive adjusted EBITDA of $147,000 in Q4, marking the first profitable quarter since going public, compared to a loss of $7.8 million in Q4 2024.
• Gross Profit: Q4 gross profit was $22.7 million, with a gross margin of 16%, up from 14.6% in the prior year.
• Cash Position: Ended Q4 with $33.6 million in cash and positive free cash flow of $3.2 million.

2. Strategic Updates and Business Highlights

• Capitated Care Model Expansion: Initiated 9 new capitated contracts in 2025, adding approximately 260,000 patient lives, with significant growth in Florida through partnerships with Elevance, Humana, and CarePlus.
• Pharmacy Revenue: Pharmacy segment revenue grew by 49.6% year-over-year to $269.2 million, driven by increased prescription volumes and reduced leakage to outside pharmacies.
• Operational Efficiency: SG&A expenses decreased by 2% year-over-year, reflecting improved operational leverage.
• Leadership Strengthening: Added key executives to the leadership team, enhancing the company's capability to scale.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected revenue between $630 million to $650 million, with approximately $150 million from capitated revenue.
• Adjusted EBITDA Guidance: Projected adjusted EBITDA between $0 million to $9 million for 2026, with anticipated negative free cash flow of $15 million to $5 million in the first quarter due to seasonal factors.
• Growth Expectations: Anticipating over 80% growth in capitated revenue for 2026, with a focus on expanding the delegated capitation model.

4. Bad News, Challenges, or Points of Concern

• Inflation Reduction Act Impact: Minor expected impact on IMBRUVICA revenue due to price negotiations, though TOI plans to mitigate this through optimization strategies.
• First Quarter Challenges: Anticipated adjusted EBITDA loss in Q1 2026 due to seasonal factors and prior year benefits from renegotiated drug distribution agreements.
• Market Competition: Concerns about potential cannibalization of fee-for-service volumes as capitated contracts grow, which may affect overall revenue growth in that segment.

5. Notable Q&A Insights

• Dispensing Revenue Drivers: Strong performance attributed to operational execution and increased patient encounters linked to capitated contracts.
• Market Expansion: Plans to double the Elevance contract in Florida and expand partnerships with Humana and CarePlus, indicating significant growth potential in Medicare Advantage populations.
• AI Efficiency: Expected to generate about $2 million in SG&A savings in 2026 through AI-related efficiencies, particularly in prior authorization processes.
• Contract Structure Resilience: Management emphasized that TOI's unique care model allows for better control over practice patterns and pricing, potentially insulating the company from adverse effects of a lower rate environment.

This summary encapsulates TOIIW's financial performance, strategic initiatives, future outlook, and key concerns as discussed in the Q4 2025 earnings call.